Tel. : 01 45 33 67 17 / E-mail : coger@coger.fr
AVANTI POLAR LIPIDS , CYGNUS , LARODAN , ADIPOGEN , MYBIOSOURCE , SERVA NORDMARK, BIOWORLD, EDGEBIO , PANREAC APPLICHEM
Ajouter au panier
Le produit a été ajouté au panier Le stock est insuffisant. unités ont été rajoutées au panier Total:
|
Stock épuisé.
En rupture de stock
|
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte
|
photos non contractuelles
Product description: Chemical. CAS: 2412270-22-3. Formula: C16H12ClN3O. MW: 297.7. CA77.1 is a novel selective chaperone-mediated autophagy (CMA) activator by increasing the expression of the lysosomal receptor for this pathway, LAMP2A, in lysosomes. Chaperone-mediated autophagy (CMA), is a selective autophagy shown to degrade neurodegeneration-related proteins such as alpha-synuclein (alpha-syn) or tau. Loss of neuronal CMA leads to altered neuronal function, selective changes in the neuronal metastable proteome and proteotoxicity. Chemical upregulation of CMA has been shown to ameliorate pathology in AD experimental mouse models, reduce brain pathology and improve disease phenotype.CA77.1 is able to activate CMA in vitro and in vivo (in contrary to it's derivative AR7 which was not suitable for in vivo application). CA77.1 is able to activate CMA in vivo, and demonstrates brain penetrance and favorable pharmacokinetics. It has been shown in animal studies that administration of CA77.1 to enhance chaperone-mediated autophagy, may help to degrade toxic pathogenic protein products such as tau proteins and has potential applications in the treatment of Alzheimer's disease.
Alerte
Veuillez saisir les champs obligatoires! |